{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:22:52Z","timestamp":1790374972347,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Project of Wuxi City, Jiangsu Province in 2023, Managed by the Administration of Traditional Chinese Medicine of Wuxi City","award":["ZYYB12"],"award-info":[{"award-number":["ZYYB12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05411-9","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:39:16Z","timestamp":1778902756000},"page":"17001-17015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ginsenoside Rh2 inhibits non-small-cell lung cancer\u00a0malignant progression through targeting AURKA"],"prefix":"10.1007","volume":"399","author":[{"given":"Yuanyuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanlan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"1","key":"5411_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/13880209.2024.2351934","volume":"62","author":"X Chen","year":"2024","unstructured":"Chen X, Yan Y, Liu Y, Yi Q, Xu Z (2024) Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial-mesenchymal transition in triple-negative breast cancer. Pharm Biol 62(1):394\u2013403","journal-title":"Pharm Biol"},{"key":"5411_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108633","volume":"163","author":"S Chung","year":"2025","unstructured":"Chung S, Sperier E, Graciano K, Hu X, Guo H, Xu J (2025) Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies. Bioorg Chem 163:108633","journal-title":"Bioorg Chem"},{"key":"5411_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1483896","volume":"15","author":"R Ding","year":"2024","unstructured":"Ding R, Kan Q, Wang T, Xiao R, Song Y, Li D (2024) Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6\/JAK2\/STAT3 pathway. Front Pharmacol 15:1483896","journal-title":"Front Pharmacol"},{"issue":"14","key":"5411_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70689","volume":"29","author":"Y Fang","year":"2025","unstructured":"Fang Y, Wang Y, Yang L, Yuan S, Gu J, Zhou Z, Fang Z, Li Y (2025) Inflammatory pathways and immune microenvironment in non-small cell lung cancer: multi-dimensional analysis and machine learning prediction. J Cell Mol Med 29(14):e70689","journal-title":"J Cell Mol Med"},{"key":"5411_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1641838","volume":"16","author":"H Gao","year":"2025","unstructured":"Gao H, Huang J, Zhang D, Li S, Long S, Qin Y (2025) Natural products as therapeutics for malignant melanoma: preclinical evidence and mechanism. Front Pharmacol 16:1641838","journal-title":"Front Pharmacol"},{"issue":"4","key":"5411_CR6","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s12094-024-03731-x","volume":"27","author":"G Gomatou","year":"2025","unstructured":"Gomatou G, Charpidou A, Li P, Syrigos N, Gkiozos I (2025) Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC. Clin Transl Oncol 27(4):1426\u20131437","journal-title":"Clin Transl Oncol"},{"key":"5411_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1633891","volume":"15","author":"Z He","year":"2025","unstructured":"He Z, Shi J, Zhu B, Tian Z, Zhang Z, Zhang C (2025) Ginsenoside Rh2 repressed the progression of prostate cancer through the mitochondrial damage induced by mitophagy and ferroptosis. Front Oncol 15:1633891","journal-title":"Front Oncol"},{"key":"5411_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells14161288","author":"M Hu","year":"2025","unstructured":"Hu M, Zheng K, Zhang L, Kan Y, Zhao J, Chen D (2025) Therapeutic strategies targeting aerobic glycolysis in cancer and dynamic monitoring of associated metabolites. Cells 14(16):1288. https:\/\/doi.org\/10.3390\/cells14161288","journal-title":"Cells"},{"issue":"1","key":"5411_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","volume":"10","author":"Q Huang","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, Li X, Dong S, Dong Z, Hu S (2025) Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther 10(1):186","journal-title":"Signal Transduct Target Ther"},{"key":"5411_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2024.111320","volume":"185","author":"A Jain","year":"2024","unstructured":"Jain A, Lokhande KB, Singh A (2024) Breaking the \u2018undruggable\u2019 barrier: revealing molecular mechanisms in Aurora kinase A\/Myc protein interplay targeting cancers. Med Hypotheses 185:111320","journal-title":"Med Hypotheses"},{"issue":"1","key":"5411_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","volume":"203","author":"H Jeon","year":"2025","unstructured":"Jeon H, Wang S, Song J, Gill H, Cheng H (2025) Update 2025: management of non-small-cell lung cancer. Lung 203(1):53","journal-title":"Lung"},{"issue":"2","key":"5411_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","volume":"6","author":"R Jin","year":"2025","unstructured":"Jin R, Neufeld L, McGaha TL (2025) Linking macrophage metabolism to function in the tumor microenvironment. Nat Cancer 6(2):239\u2013252","journal-title":"Nat Cancer"},{"key":"5411_CR13","doi-asserted-by":"crossref","unstructured":"Kim MH, Kim S-G, Kim D-W\u00a0(2024) A novel dual-labeled peptide for multimodal imaging of EGFR with L858R mutation. Current Radiopharmaceuticals 17(2):174\u2013183","DOI":"10.2174\/0118744710249198231002055810"},{"key":"5411_CR14","doi-asserted-by":"crossref","unstructured":"Kraim K, Boudjedir A, Saihi Y, Chikh FZ, Slatnia Y, Ferkous F (2024) In silico structure-based screening of potential anticancer bioactive natural constituents from African natural products. Letters in Drug Design & Discovery 21(16):3479\u20133492","DOI":"10.2174\/0115701808280302240117055932"},{"issue":"4","key":"5411_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/0115665232340926241105064739","volume":"25","author":"CL Li","year":"2025","unstructured":"Li CL, Ma XY, Yi P (2025a) The role of immunotherapy in lung cancer treatment: current strategies, future directions, and insights into metastasis and immune microenvironment. Current gene therapy 25(4):453\u2013466","journal-title":"Current gene therapy"},{"key":"5411_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgaf023","author":"S Li","year":"2025","unstructured":"Li S, Zhang M, Gao Y, Zhao C, Liao S, Zhao X, Ning Q, Tang S (2025b) Mechanisms of tumor-associated macrophages promoting tumor immune escape. Carcinogenesis 46(2):bgaf023. https:\/\/doi.org\/10.1093\/carcin\/bgaf023","journal-title":"Carcinogenesis"},{"issue":"4","key":"5411_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/CAD.0000000000001682","volume":"36","author":"X Li","year":"2025","unstructured":"Li X, Guo Y, Qi Z, Zheng Y (2025c) WDR62 mediates MAPK\/ERK pathway to stimulate DNA damage repair and attenuate cisplatin sensitivity in lung adenocarcinoma. Anticancer Drugs 36(4):319\u2013327","journal-title":"Anticancer Drugs"},{"issue":"1","key":"5411_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10020-024-00813-y","volume":"30","author":"X Liu","year":"2024","unstructured":"Liu X, Li J, Huang Q, Jin M, Huang G (2024a) Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-\u03b1\/PDK4 axis in non-small cell lung cancer. Molecular Medicine (Cambridge, Mass) 30(1):56","journal-title":"Molecular Medicine (Cambridge, Mass)"},{"key":"5411_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162805","author":"H Liu","year":"2024","unstructured":"Liu H, Cali Daylan AE, Yang J, Tanwar A, Borczuk A, Zhang D, Chau V, Li S, Ge X, Halmos B et al (2024b) Aurora kinase A inhibition potentiates platinum and radiation cytotoxicity in non-small-cell lung cancer cells and induces expression of alternative immune checkpoints. Cancers 16(16):2805. https:\/\/doi.org\/10.3390\/cancers16162805","journal-title":"Cancers"},{"key":"5411_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173700","author":"J Liu","year":"2025","unstructured":"Liu J, Deng Y, Pu Z, Miao Y, Hao Z, Wang H, Zhang S, Liu H, Wang J, Lv Y et al (2025a) The AURKA inhibitor alters the immune microenvironment and enhances targeting B7-H3 immunotherapy in glioblastoma. JCI Insight 10(5):e173700. https:\/\/doi.org\/10.1172\/jci.insight.173700","journal-title":"JCI Insight"},{"key":"5411_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121783","author":"R Liu","year":"2025","unstructured":"Liu R, Zhan J, Lai Y, Ma Y, Wang W, Jiang L, Shao Y (2025b) Astragaloside-Brucea javanica oil nanoemulsion regulates glycolysis in oral squamous cell carcinoma through AURKA-mediated PI3K\/AKT\/HIF-1\u03b1 pathway. Pharmaceuticals (Basel, Switzerland) 18(12):1783. https:\/\/doi.org\/10.3390\/ph18121783","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"5411_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217972","volume":"632","author":"X Liu","year":"2025","unstructured":"Liu X, Li H, Yuan M, Wan J, Guo J, Dong X, Jin X, Yang C, Wang G (2025c) The epigenetic landscape of tumor-associated macrophages: orchestrating immune evasion in the tumor microenvironment. Cancer Lett 632:217972","journal-title":"Cancer Lett"},{"key":"5411_CR23","doi-asserted-by":"publisher","unstructured":"Lv C, Liu Y, Zhang H (2025) The oncogenic role of AURKA in gastric cancer: mechanisms, pathways, and clinical relevance. Carcinogenesis bgaf054. https:\/\/doi.org\/10.1093\/carcin\/bgaf054","DOI":"10.1093\/carcin\/bgaf054"},{"issue":"12","key":"5411_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115064","volume":"43","author":"Y Mao","year":"2024","unstructured":"Mao Y, Xia Z, Xia W, Jiang P (2024) Metabolic reprogramming, sensing, and cancer therapy. Cell Rep 43(12):115064","journal-title":"Cell Rep"},{"issue":"18","key":"5411_CR25","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.2174\/0115701808354285241109140805","volume":"21","author":"L Mengshu","year":"2024","unstructured":"Mengshu L, Meiqi L, Yixuan C, Qing G (2024) Molecular mechanism of finerenone in treating diabetic nephropathy based on bioinformatics. Lett Drug des Discov 21(18):4389\u20134399","journal-title":"Lett Drug des Discov"},{"issue":"2","key":"5411_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17(2):93\u2013115","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5411_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/1874471016666230829100703","volume":"17","author":"K Ozan","year":"2024","unstructured":"Ozan K, Fadime D (2024) An investigation of the relationship between 18F-FDG PET\/CT parameters of primary tumors and lymph node metastasis in resectable non-small cell lung cancer. Current Radiopharmaceuticals 17(1):111\u2013116","journal-title":"Current Radiopharmaceuticals"},{"issue":"Pt 3","key":"5411_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.semcancer.2022.09.007","volume":"86","author":"S Paul","year":"2022","unstructured":"Paul S, Ghosh S, Kumar S (2022) Tumor glycolysis, an essential sweet tooth of tumor cells. Semin Cancer Biol 86(Pt 3):1216\u20131230","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"5411_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3724\/abbs.2022039","volume":"54","author":"K Peng","year":"2022","unstructured":"Peng K, Luo T, Li J, Huang J, Dong Z, Liu J, Pi C, Zou Z, Gu Q, Liu O et al (2022) Ginsenoside Rh2 inhibits breast cancer cell growth via ER\u03b2-TNF\u03b1 pathway. Acta Biochim Biophys Sin 54(5):647\u2013656","journal-title":"Acta Biochim Biophys Sin"},{"key":"5411_CR30","doi-asserted-by":"publisher","DOI":"10.2174\/1874467217666230721123554","volume":"17","author":"XJ Qian","year":"2024","unstructured":"Qian XJ, Wang JW, Liu JB, Yu X (2024) The mediating role of miR-451\/ETV4\/MMP13 signaling axis on epithelialmesenchymal transition in promoting non-small cell lung cancer progression. Curr Mol Pharmacol 17:e210723218988","journal-title":"Curr Mol Pharmacol"},{"issue":"7","key":"5411_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","volume":"22","author":"Z Rahal","year":"2025","unstructured":"Rahal Z, El Darzi R, Moghaddam SJ, Cascone T, Kadara H (2025) Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nature reviews Clinical oncology 22(7):463\u2013482","journal-title":"Nature reviews Clinical oncology"},{"key":"5411_CR32","doi-asserted-by":"crossref","unstructured":"Rani K, Mazumder A, Gupta MK, Arora T (2024) Unlocking therapeutic potential: molecular docking insights into Aurora kinase A inhibitors patented and published from 2011-2020 for innovative anticancer drug design. Letters in Drug Design & Discovery 21(18):4293\u20134309","DOI":"10.2174\/0115701808310599241003080546"},{"issue":"11","key":"5411_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","volume":"22","author":"M Reck","year":"2025","unstructured":"Reck M, Frost N, Peters S, Fox BA, Ferrara R, Savai R, Barlesi F (2025) Treatment of NSCLC after chemoimmunotherapy - are we making headway? Nat Rev Clin Oncol 22(11):806\u2013830","journal-title":"Nat Rev Clin Oncol"},{"key":"5411_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217865","volume":"628","author":"H Sabit","year":"2025","unstructured":"Sabit H, Adel A, Abdelfattah MM, Ramadan RM, Nazih M, Abdel-Ghany S, El-Hashash A, Arneth B (2025) The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities. Cancer Lett 628:217865","journal-title":"Cancer Lett"},{"issue":"6","key":"5411_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","volume":"25","author":"KL Simpson","year":"2025","unstructured":"Simpson KL, Rothwell DG, Blackhall F, Dive C (2025) Challenges of small cell lung cancer heterogeneity and phenotypic plasticity. Nat Rev Cancer 25(6):447\u2013462","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"5411_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02818-x","volume":"42","author":"A Sinha","year":"2025","unstructured":"Sinha A, Ghosh D, Karati D (2025) Tumor microenvironment and immunotherapy: from bench to bedside. Medical Oncology 42(7):244","journal-title":"Medical Oncology"},{"key":"5411_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052049","author":"B Smolarz","year":"2025","unstructured":"Smolarz B, \u0141ukasiewicz H, Samulak D, Piekarska E, Ko\u0142aci\u0144ski R, Romanowicz H (2025) Lung cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature). Int J Mol Sci 26(5):2049. https:\/\/doi.org\/10.3390\/ijms26052049","journal-title":"Int J Mol Sci"},{"key":"5411_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.109744","volume":"187","author":"A Sultana","year":"2025","unstructured":"Sultana A, Alam MS, Khanam A, Liang H (2025) Unraveling the molecular landscape of non-small cell lung cancer: integrating bioinformatics and statistical approaches to identify biomarkers and drug repurposing. Comput Biol Med 187:109744","journal-title":"Comput Biol Med"},{"issue":"1","key":"5411_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s41065-024-00351-x","volume":"161","author":"L Tang","year":"2024","unstructured":"Tang L, Ruan Y, Wang B, Zhang M, Xue J, Wang T (2024) Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt\/\u03b2-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo. Hereditas 161(1):48","journal-title":"Hereditas"},{"issue":"7","key":"5411_CR40","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1007\/s00210-025-03876-8","volume":"398","author":"BK Utpal","year":"2025","unstructured":"Utpal BK, Bouenni H, Zehravi M, Sweilam SH, Mortuza MR, Arjun U, Shanmugarajan TS, Mahesh PG, Roja P, Dodda RK et al (2025) Exploring natural products as apoptosis modulators in cancers: insights into natural product-based therapeutic strategies. Naunyn-Schmiedeberg\u2019s archives of pharmacology 398(7):8189\u20138214","journal-title":"Naunyn-Schmiedeberg's archives of pharmacology"},{"issue":"4","key":"5411_CR41","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s10637-015-0258-y","volume":"33","author":"K Venkatakrishnan","year":"2015","unstructured":"Venkatakrishnan K, Kim TM, Lin CC, Thye LS, Chng WJ, Ma B, Chen MH, Zhou X, Liu H, Kelly V et al (2015) Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational new drugs 33(4):942\u2013953","journal-title":"Investigational new drugs"},{"issue":"1","key":"5411_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02878-5","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu J, Xu J, Ji Z (2025) The expression and prognosis for Aurora kinases in human non-small cell lung cancer. Discover Oncol 16(1):1021","journal-title":"Discover Oncol"},{"key":"5411_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113912","volume":"156","author":"S Xiaodan","year":"2022","unstructured":"Xiaodan S, Ying C (2022) Role of ginsenoside Rh2 in tumor therapy and tumor microenvironment immunomodulation. Biomed Pharmacother 156:113912","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5411_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02211-1","volume":"23","author":"S Xiong","year":"2025","unstructured":"Xiong S, Liu Z, Yao J, Huang S, Ding X, Yu H, Lin T, Zhang X, Zhao F (2025) HIF-1\u03b1 regulated GLUT1-mediated glycolysis enhances Treponema pallidum-induced cytokine responses. Cell Commun Signal 23(1):219","journal-title":"Cell Commun Signal"},{"key":"5411_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1610998","volume":"16","author":"H Xue","year":"2025","unstructured":"Xue H, Fan Y, Li Y, Zhao Q, Zhang X, Zhao P, Liu Z (2025) Tumor-infiltrating lymphocytes in NSCLC: from immune surveillance to immunotherapy. Front Immunol 16:1610998","journal-title":"Front Immunol"},{"key":"5411_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbiomolbio.2025.05.003","volume":"197","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Tao Y, Du G, Huang T, Chen S, Fan L, Zhang N (2025) Advances in the mechanisms of HIF-1\u03b1-enhanced tumor glycolysis and its relation to dedifferentiation. Prog Biophys Mol Biol 197:1\u201310","journal-title":"Prog Biophys Mol Biol"},{"issue":"3","key":"5411_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00432-025-06164-3","volume":"151","author":"QY Zhao","year":"2025","unstructured":"Zhao QY, Liu WJ, Wang JG, Li H, Lv JL, Wang Y, Wang C (2025) Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism. J Cancer Res Clin Oncol 151(3):126","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05411-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05411-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05411-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:51:48Z","timestamp":1787669508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05411-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5411"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05411-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consents were obtained from all participants, and this study was permitted by the Ethics Committee of Wuxi No. 2 Chinese Medicine Hospital (Approval Number: 2023SWZG01). The research has been carried out in accordance with the World Medical Association Declaration of Helsinki, and all subjects have provided written informed consent. Animal studies were performed in compliance with the ARRIVE guidelines and the Basel Declaration. All animals received humane care according to the National Institutes of Health (USA) guidelines. All animal experiments were approved by the Animal Ethics Committee of Wuxi No. 2 Chinese Medicine Hospital (Approval Number: 2023SWZG05).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}